Interview with Wolf Kupatt, Managing Director, Baxter Germany
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
Address: Am Karlsbad 15 / 10785 Berlin
Tel: +49 (0) 30 2639 2880
Cytolon is the first technology company to fulfill the central needs of personalized medicine. Personalized medicine is based on matching the patient´s personal genomic and histocompatibility data with the characteristics of a given product in order to achieve the best possible therapeutic effect. As medical treatments become more personalized, it will be increasingly important to be able to provide fast and accurate matching of patient data with therapeutic products for hundreds of thousands of patient cases at any time. A comprehensive solution can only be provided by intelligent internet-based matching platforms. As of today, there are no matching platforms that fulfill these needs. Cytolon was created to fill this gap.
Cytolon´s corporate mission is to be the world’s first trusted source for obtaining the correct, best-matched personalized product in a timely and cost-effective manner. Cytolon meets the requirements of personalized medicine through high performance matching, comprehensive logistics and secure data management for clinical development.
As allogeneic cord blood units and the stem cells contained within them are the first existing personalized products in clinical practice, Cytolon is initially focusing on this market. An accurate, timely matching process is imperative as a cord blood unit (CBU) must perfectly match the histocompatibility antigens and genetic needs of the patient and must be delivered within days.
Cytolon has developed a proprietary, patent-pending, global internet-based cord blood matching platform called CordMatch®. This platform is unique, as it integrates product search and matching, selection and logistics plus billing and follow-up.
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
See our Cookie Privacy Policy Here
